NutriDex

The Supplement Research Compendium
🌾

Xylooligosaccharides (XOS)

Xylo-oligosaccharides

A low-dose, potently bifidogenic prebiotic fiber — effective microbiome shifts at just 1-4 g/day

Moderate evidence 🌾Prebiotics & Fibers🛡️Gut & Immune

✚ Updated · How we grade evidence

Evidence tier
Moderate
Research weight
Citations
7 verified / 7
Classification
Prebiotics & Fibers
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.

What is Xylooligosaccharides (XOS)?

Xylooligosaccharides (XOS) (Xylo-oligosaccharides) is a prebiotic fiber used for strongly bifidogenic at low doses: significant rise in fecal bifidobacterium at 1.4-2.8 g/day (dose-dependent) and at 8 g/day, frequently exceeding the efficiency of fos/inulin gram-for-gram. NutriDex grades the human evidence as Moderate. Xylo-oligosaccharides (XOS) are short chains of xylose sugars derived from plant hemicellulose (arabinoxylan) that resist digestion and are selectively fermented in the colon. Their best-documented effect is bifidogenic: small human RCTs and crossover studies consistently show XOS raises fecal Bifidobacterium at unusually low doses (1.4-8 g/day), often more efficiently than inulin or FOS. Evidence for downstream clinical endpoints is thinner: a single small RCT in type 2 diabetes reported improvements in glucose, fructosamine, and LDL, and small trials suggest stool-frequency benefit in constipation, but large confirmatory trials and meta-analyses specific to XOS are lacking. Overall the microbiome/bifidogenic effect is moderately well-supported; metabolic and bowel claims remain preliminary.

Purported Benefits

✓Strongly bifidogenic at low doses: significant rise in fecal Bifidobacterium at 1.4-2.8 g/day (dose-dependent) and at 8 g/day, frequently exceeding the efficiency of FOS/inulin gram-for-gram
✓Increases colonic short-chain fatty acid (SCFA) production, particularly via Bifidobacterium-driven cross-feeding, supporting gut barrier and lower colonic pH
✓Glycemic/lipid signals in type 2 diabetes: an 8-week RCT (4 g/day) reported ~8% lower fasting glucose, ~21% lower fructosamine, and reduced total/LDL and oxidized LDL cholesterol (single small trial, needs replication)
✓Improves stool frequency in functional constipation: XOS (3-10 g/day) improved Bristol stool scores and constipation symptom scores; pooled non-digestible-oligosaccharide data show increased defecation frequency
✓Well tolerated at effective doses thanks to slow, low-volume fermentation, so prebiotic shifts occur with minimal gas compared with higher-dose inulin/FOS

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Increases fecal Bifidobacterium (bifidogenic)Multiple small RCTs show dose-dependent bifidogenesis at 1.4-8 g/day; consistent but surrogate microbiome endpoint, no clinical outcome. Moderate ↑ benefit · moderate 3
Improves stool frequency in constipationOne XOS RCT plus pooled non-digestible-oligosaccharide meta-analysis show better stool frequency/Bristol scores; XOS-specific evidence still thin. Preliminary ↑ benefit · small 2
Lowers fasting glucose / improves lipids in type 2 diabetesBased on a single small 8-week RCT (n=26) at 4 g/day; needs replication before any reliance. Preliminary ↑ benefit 1
Raises colonic SCFA productionMechanistic cross-feeding effect inferred mostly from reviews; little direct human SCFA-measurement data in the entry. Preliminary ↑ benefit 1
GI tolerability (minimal gas at effective dose)Trials report no significant GI side effects at 1.4-2.8 g/day; favorable vs higher-dose FOS/inulin but not the primary endpoint. Preliminary ↑ benefit · small 1

Dosing & Compounds

Typical Dose
Typical effective dose is 1.4-8 g/day; bifidogenic effects appear from ~1.4-2.8 g/day, with 4 g/day used in the diabetes trial and up to 8-10 g/day in constipation/immune studies. Taken once daily as powder mixed in water/food or as capsules, with or without meals; start low (1-2 g) and titrate.
Active Compounds
Supplement ingredient PreticX (AIDP); featured in products such as NOW Prebiotic Bifido BoostPowders, capsules, and gummies; often combined with probiotics as synbiotics (e.g., with Bifidobacterium animalis subsp. lactis)Added to functional foods and beverages as a low-dose prebiotic and mild sweetenerFood sources (small amounts): bamboo shoots, rice bran/husk, corn cobs, honey, and fruits such as apple and pear skins

Safety & Cautions

Generally well tolerated and notably low-gas relative to inulin/FOS because it is fermented slowly at low doses. XOS is a fermentable fiber (low-FODMAP-class oligosaccharide of the GOS/fructan family) so it can still cause bloating, flatulence, or loose stools, especially above ~10 g/day or in people with IBS sensitive to fermentable carbohydrates. As with all viscous/fermentable fibers, take with adequate fluid and separate from oral medications (fibers can delay or reduce drug absorption). People with IBS, SIBO, or on FODMAP-restricted diets should introduce cautiously; consult a clinician if diabetic and adjusting glucose-lowering therapy. Educational only — always check with your doctor or pharmacist before combining Xylooligosaccharides (XOS) with any medicine.

Key Studies

Meta-analysis Chen 2025 ✓ Full text
Systematic review/meta-analysis of 20 RCTs (1,786 participants) of non-digestible oligosaccharides: overall increased stool frequency (SMD 0.35, 95% CI 0.17-0.52); the included XOS trial (8 g/day) significantly raised defecation frequency and Bifidobacterium (p=0.008).
RCT Yi 2024 ✓ Full text
Randomized trial in functional constipation: XOS (3-10 g/day) for one month improved Bristol stool scores and Cleveland constipation scores with targeted enrichment of Bifidobacterium.
RCT Finegold 2014 ✓ PubMed
Double-blind trial in 32 healthy adults: XOS at 1.4 and 2.8 g/day for 8 weeks dose-dependently increased fecal Bifidobacterium (greater at 2.8 g) without significant GI side effects; lactobacilli unchanged.
RCT Childs 2014 ✓ PubMed
Double-blind placebo-controlled factorial crossover in healthy adults: XOS 8 g/day for 21 days induced significant bifidogenesis and modulated markers of immune function, alone and as a synbiotic with B. animalis subsp. lactis Bi-07.
RCT Sheu 2008 ✓ PubMed
In 26 adults with type 2 diabetes, 4 g/day XOS for 8 weeks lowered fasting glucose ~8%, fructosamine ~21%, and reduced total/LDL and oxidized LDL cholesterol vs placebo.
Review Nogueira-Prieto 2025 ✓ PubMed
Food & Function review concludes XOS are resistant to mammalian digestion but fermentable by beneficial gut bacteria, exerting a bifidogenic effect that stimulates SCFA production, suppresses pathogens, and may improve lipid profiles and inflammation.
Review Yu 2022 ✓ Source
Comprehensive review of XOS production and nutritional properties summarizing prebiotic, bifidogenic, glycemic, lipid-lowering, and SCFA-promoting effects and effective human doses of ~1-8 g/day.
7 sources cited · 7 verified Search all studies on PubMed ↗

Common questions about Xylooligosaccharides (XOS)

What is Xylooligosaccharides (XOS) used for?

Xylooligosaccharides (XOS) is most often taken for Strongly bifidogenic at low doses: significant rise in fecal Bifidobacterium at 1.4-2.8 g/day (dose-dependent) and at 8 g/day, frequently exceeding the efficiency of FOS/inulin gram-for-gram, Increases colonic short-chain fatty acid (SCFA) production, particularly via Bifidobacterium-driven cross-feeding, supporting gut barrier and lower colonic pH, Glycemic/lipid signals in type 2 diabetes: an 8-week RCT (4 g/day) reported ~8% lower fasting glucose, ~21% lower fructosamine, and reduced total/LDL and oxidized LDL cholesterol (single small trial, needs replication), Improves stool frequency in functional constipation: XOS (3-10 g/day) improved Bristol stool scores and constipation symptom scores; pooled non-digestible-oligosaccharide data show increased defecation frequency. A low-dose, potently bifidogenic prebiotic fiber — effective microbiome shifts at just 1-4 g/day

Does Xylooligosaccharides (XOS) work — what does the evidence say?

Moderate evidence. Several controlled trials; effects real but modest or context-dependent. Xylo-oligosaccharides (XOS) are short chains of xylose sugars derived from plant hemicellulose (arabinoxylan) that resist digestion and are selectively fermented in the colon. Their best-documented effect is bifidogenic: small human RCTs and crossover studies consistently show XOS raises fecal Bifidobacterium at unusually low doses (1.4-8 g/day), often more efficiently than inulin or FOS. Evidence for downstream clinical endpoints is thinner: a single small RCT in type 2 diabetes reported improvements in glucose, fructosamine, and LDL, and small trials suggest stool-frequency benefit in constipation, but large confirmatory trials and meta-analyses specific to XOS are lacking. Overall the microbiome/bifidogenic effect is moderately well-supported; metabolic and bowel claims remain preliminary.

What is the typical dose of Xylooligosaccharides (XOS)?

Typical effective dose is 1.4-8 g/day; bifidogenic effects appear from ~1.4-2.8 g/day, with 4 g/day used in the diabetes trial and up to 8-10 g/day in constipation/immune studies. Taken once daily as powder mixed in water/food or as capsules, with or without meals; start low (1-2 g) and titrate.

Is Xylooligosaccharides (XOS) safe? Any cautions or side effects?

Generally well tolerated and notably low-gas relative to inulin/FOS because it is fermented slowly at low doses. XOS is a fermentable fiber (low-FODMAP-class oligosaccharide of the GOS/fructan family) so it can still cause bloating, flatulence, or loose stools, especially above ~10 g/day or in people with IBS sensitive to fermentable carbohydrates. As with all viscous/fermentable fibers, take with adequate fluid and separate from oral medications (fibers can delay or reduce drug absorption). People with IBS, SIBO, or on FODMAP-restricted diets should introduce cautiously; consult a clinician if diabetic and adjusting glucose-lowering therapy.

How many studies support Xylooligosaccharides (XOS)?

NutriDex cites 7 sources for Xylooligosaccharides (XOS), graded "Moderate".

Cite this page
APA

Peh, D. (2026). Xylooligosaccharides (XOS) (Xylo-oligosaccharides): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/xos

BibTeX
@misc{nutridex_xos,
  author       = {Peh, Daryl},
  title        = {Xylooligosaccharides (XOS) (Xylo-oligosaccharides): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/xos},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances